Clinical trial summaries for GLP-1 receptor agonists, including cardiovascular outcomes, glycaemic control, obesity, kidney outcomes, tolerability, and practice implications.
A prespecified, descriptive subgroup analysis of a phase 2 survodutide trial examined how sex and baseline BMI shaped weight and waist outcomes in 387 adults with overweight or obesity. PICO summary and expert commentary.
Post-hoc STEP 6 subgroup analysis of semaglutide versus placebo in 401 Japanese and Korean adults with overweight or obesity, testing whether sex, type 2 diabetes, and other baseline factors modify weight loss. PICO summary and expert commentary.
A phase 2 substudy found retatrutide produced dose-related reductions in total body fat mass at 36 weeks versus placebo and dulaglutide in type 2 diabetes. PICO summary and expert commentary.
A small acute mechanistic crossover study testing whether exenatide-glucagon co-infusion raises myocardial glucose uptake and a diastolic strain-rate marker in eight adults with type 2 diabetes. PICO summary and expert commentary.
A secondary analysis of the COORDINATE-Diabetes trial found that up to one-third of patients with Type 2 diabetes and atherosclerotic cardiovascular disease stopped their SGLT-2i or GLP-1RA within 12 months, with cost and side effects among the cited reasons. PICO summary and expert commentary.
A post hoc analysis of the ADJUNCT ONE and ADJUNCT TWO trials identifies who discontinues adjunctive liraglutide in type 1 diabetes: longer disease duration, undetectable C-peptide, and lower BMI. PICO summary and expert commentary.
An early-phase trial of the GLP-1/FGF21 dual agonist HEC88473 reported dose-proportional liver fat reduction and improved glycaemic control over 5 weeks in patients with MASLD and type 2 diabetes. PICO summary and expert commentary.
A 16-week randomized trial found combined training lowered GLP-1 and amylin and raised DPP-4 in adults with type 2 diabetes and overweight, without a demonstrated glycaemic benefit. PICO summary and expert commentary.
A phase 1, double-blind, placebo-controlled study of titrated noiiglutide (SHR20004) in obese Chinese adults without diabetes reported good tolerability and dose-related weight loss, with PICO summary and expert commentary.
A first-in-human phase 1 trial of oral amycretin in overweight or obesity found it safe and tolerable, with dose-dependent gastrointestinal effects and exploratory weight loss. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
